Clinical trials: Subclinical Primary Aldosteronism
Type 2 Diabetes, Chronic Kidney Diseases
Subclinical Primary Aldosteronism in Diabetes At-Risk for Kidney Disease
The aim of this protocol is to assess the presence and severity of primary aldosteronism pathophysiology in patients with type 2 diabetes who have, or are at-risk for developing, chronic kidney disease.
- Trial name
- SubPA-DKD (NCT06190158)
- Testing
- Oral sodium suppression test, Saline suppression test, Captopril suppression test
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Brigham and Women's Hospital
Essential Hypertension, Liver Cancer
A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China
The human gut microbiome has been associated with many health factors but variability between studies limits the exploration of effects between them.
- Conditions
- Essential Hypertension, Liver Cancer, Nasopharyngeal Cancer, Pancreatic Cancer
- Trial name
- NCT05638269
- Testing
- no intervention
- Where
- 50 sites in China
- Volunteers
- 12,000 people, healthy volunteers welcome
- Sponsor
- Zhujiang Hospital
Subclinical Primary Aldosteronism
Early Aldo Blockade in Subclinical PA
This trial aims to evaluate the preventive effect of early intervention with eplerenone, a highly selective nonsteroidal mineralocorticoid receptor antagonist, against new-onset hypertension in normotensive patients with…
- Trial name
- EARLY-PA (NCT07727252)
- Testing
- Eplerenone
- Volunteers
- 880 people
- Sponsor
- Xinjiang Medical University